secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001493152-23-021642
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Q1 net product revenue up 37% to $5.8M; operating loss down 88%; reaffirms path to EBITDA break-even
--------------------------------------------------------------------------------

- Phexxi net product sales $5.8M (+37% YoY); total operating expenses $9.4M (-72% YoY).
- Loss from operations decreased 88% to $3.6M; net loss $(2.4)M ($1.85/share) vs $(32.0)M ($360.25/share).
- Cash at March 31: $1.5M (restricted+unrestricted) down from $4.8M; on track for quarterly EBITDA break-even by year-end 2023.
- Appointed Ivy Zhang as CFO effective April 13, 2023; effectuated reverse stock split on May 18, 2023.
- Filed patent infringement suit against Padagis on June 1, 2023; triggers 30-month FDA stay on generic Phexxi approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223021642/0001493152-23-021642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223021642/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-021642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer